Research News

A recent study by the University of Eastern Finland and Kuopio University Hospital shows that carnitine intake in the first postnatal weeks promotes better growth and larger brain size at term equivalent age in very preterm infants. Carnitine intake from breast milk in particular seems to be associated with better growth. The findings were published in Nutrients.

Advances inin vivoiron-based coordination assembly have enabled the simultaneous detection and treatment of iron-overload disorders. Specific interactions between local FeIIIand organic ligands (e.g., indocyanine green and lecithin) facilitate magnetic resonance imaging with enhanced sensitivity and photoacoustic imaging with high contrast, thus overcoming the longstanding limitations of traditional iron quantification approaches.

Tata 1mg, a digital healthcare platform, on Friday announced that one-third of the people who tested for HbA1c at Tata 1mg Labs, were found to have diabetes, with the highest incidence reported among the 40-60 years age group.

In Alzheimer's disease, the degeneration of brain cells is linked to formation of toxic protein aggregates and deposits known as amyloid plaques. Similar processes play an important role also in type 2 diabetes. A research team under the lead of the Technical University of Munich has now developed “mini-proteins”, so-called peptides, which are able to bind the proteins that form amyloids and prevent their aggregation into cytotoxic amyloids.

How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it and the body until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to a series of precise parameters.

The costliness of drug development and the limitations of studying physiological processes in the lab are two separate scientific issues that may share the same solution.

New findings from a pre-specified analysis of DELIVER Phase III trial data show that AstraZeneca’s Farxiga (dapagliflozin) improved symptom burden and health-related quality of life in patients with heart failure (HF) and mildly reduced or preserved ejection fraction (EF) compared with placebo1. The results were presented today at the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, Illinois, US, and are currently in press in the Journal of the American College of Cardiology.

Pioneering artificial intelligence (AI) which automatically diagnoses lung diseases – such as tuberculosis and pneumonia – could ease winter pressures on hospitals, University of the West of Scotland researchers believe.

Tuberculosis and pneumonia – potentially serious infections which mainly affect the lungs – often require a combination of different diagnostic tests – such as CT scans, blood tests, X-rays, and ultrasounds. These tests can be expensive, with often lengthy waiting times for results.

In patients meeting the eligibility requirements for the DAPA-CKD trial, dapagliflozin is likely to be a cost effective treatment within the UK, German, and Spanish health care systems, as per new research.